What question did this study set out to answer?

This research aims to evaluate the effect of mineralocorticoid receptor antagonists (MRAs) on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction (HFPEF).

October 13, 2015Open Access

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review

Key Points

This research aims to evaluate the effect of mineralocorticoid receptor antagonists (MRAs) on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction (HFPEF).
Conducted a meta-analysis and systematic review of available studies on MRA therapy.

Structured PICO

Does mineralocorticoid receptor antagonist (MRA) therapy improve cardiac structure and function in patients with asymptomatic diastolic dysfunction or HFpEF?

Population

Patients with asymptomatic diastolic dysfunction or heart failure with preserved ejection fraction (HFpEF)

Intervention

Mineralocorticoid receptor antagonists (MRA) therapy

Outcome

Diastolic function, markers of cardiac fibrosis, and left ventricular (LV) mass or dimensionssurrogate

MRA therapy improves surrogate markers of diastolic function and cardiac fibrosis in patients with asymptomatic diastolic dysfunction or HFpEF.

Abstract

MRA therapy in patients with asymptomatic diastolic dysfunction or HFPEF is associated with significant improvement in diastolic function and markers of cardiac fibrosis without a significant change in LV mass or dimensions.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper